ImmuPharma plc

IMM.L · LSE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-£2,483-£2,922-£3,029-£6,587
Dep. & Amort.£64£38£118£114
Deferred Tax£0£0£0£0
Stock-Based Comp.£88£140£160£616
Change in WC£69£470-£429£632
Other Non-Cash£494£910£833£392
Operating Cash Flow-£1,769-£1,364-£2,347-£4,833
Investing Activities
PP&E Inv.-£2£0-£106-£51
Net Acquisitions£0£0£0£0
Inv. Purchases-£75£0£0£0
Inv. Sales/Matur.£1,364£0£0£0
Other Inv. Act.£6£189£29£1
Investing Cash Flow£1,294£189-£77-£50
Financing Activities
Debt Repay.£0£0£0-£723
Stock Issued£0£1,481£2,351£3,550
Stock Repurch.£0£0£0£0
Dividends Paid£0£0£0£0
Other Fin. Act.£500-£759-£803-£2,125
Financing Cash Flow£500£722£1,548£702
Forex Effect£4-£6-£105-£31
Net Chg. in Cash£28-£459-£982-£4,213
Supplemental Information
Beg. Cash£208£668£1,649£5,862
End Cash£237£208£668£1,649
Free Cash Flow-£1,771-£1,364-£2,453-£4,884